MMWR: Human Papillomavirus Vaccination Coverage Among Adolescents, 2007-2013, and Postlicensure Vaccine Safety Monitoring, 2006-2014 – United States

To assess progress with HPV vaccination coverage among adolescents aged 13–17 years, characterize adherence with recommendations for HPV vaccination by the 13th birthday, and describe HPV vaccine adverse reports received postlicensure, CDC analyzed data from the 2007–2013 National Immunization Survey-Teen (NIS-Teen) and national postlicensure vaccine safety data among females and males. Vaccination coverage with =1 dose of any HPV vaccine increased significantly from 53.8% (2012) to 57.3% (2013) among adolescent girls and from 20.8% (2012) to 34.6% (2013) among adolescent boys. Receipt of =1 dose of HPV among girls by age 13 years increased with each birth cohort; however, missed vaccination opportunities were common. Postlicensure monitoring data continue to indicate that HPV4 is safe. Improving practice patterns so that clinicians use every opportunity to recommend HPV vaccines and address questions from parents can help realize reductions in vaccine-preventable infections and cancers caused by HPV.